Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Spark, Genable Technologies Collaboration on Rare Gene Therapy

March 25, 2014 2:04 pm | News | Comments

Spark Therapeutics and Genable Technologies announced that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. Read more...    

New Cancer Drug Manipulates Signaling, Energy Systems

March 25, 2014 1:59 pm | News | Comments

Researchers have developed a new drug that can manipulate the body’s natural signaling and energy systems, allowing the body to attack and shut down cancerous cells. Read more...                     

Study Questions First-Line Treatment for Advanced Sarcoma

March 25, 2014 1:50 pm | News | Comments

A new study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor. Read more...                 


Marijuana Pill, Spray May Ease Some MS Symptoms

March 25, 2014 1:37 pm | News | Comments

A new guideline from the American Academy of Neurology states that oral cannabis, or medical marijuana pills, and oral medical marijuana spray may ease the symptoms of multiple sclerosis (MS). Read more...          

Pfizer's Xalkori Extends Lung Cancer Survival

March 25, 2014 1:28 pm | News | Comments

Pfizer announced that PROFILE 1014, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) when compared to standard platinum-based chemotherapy regimens. Read more...

New Research Seeks DNA Vaccine Against HIV, Hep C

March 25, 2014 11:29 am | News | Comments

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with researchers applying for a patent based on groundbreaking new research. Read more...         

Ferrer, Medimetriks in Licensing Agreement for Impetigo Drug

March 25, 2014 11:20 am | News | Comments

Medimetriks Pharmaceuticals Inc. announced a licensing agreement with Ferrer for the commercialization rights to Ozenoxacin 1% Cream in the United States. Ozenoxacin is a novel, bactericidal non-fluorinated quinolone in development as a topical treatment for impetigo. Read more...

Discovery May Help Predict Lung Cancer Treatment Success

March 25, 2014 10:01 am | News | Comments

Scientists have discovered the structure of an abnormal protein which causes an aggressive type of lung cancer, according to new research. Read more...                             


Agios Enrolls First Patient in Phase 1 Cancer Trial

March 24, 2014 3:23 pm | News | Comments

Agios Pharmaceuticals Inc. announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation. Read more...           

Statins May Provide Cough Relief to Lung Disease Patients

March 24, 2014 3:18 pm | News | Comments

Common cholesterol-lowering drugs could provide relief to patients suffering from a chronic lung disease, a study has shown. The drugs- known as statins- were found to help alleviate the chronic coughing associated with the disease for some patients. Read more...

Pfizer Releases First Phase 3 Tofacitinib Psoriasis Results

March 24, 2014 3:01 pm | News | Comments

Pfizer Inc. announced detailed results from OPT Compare, a Phase 3 study of tofacitinib, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Read more...     

Ariad Launches Phase 2 Lung Cancer Trial

March 24, 2014 2:46 pm | News | Comments

Ariad Pharmaceuticals Inc. announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. Read more...    

Drugs Fail to Reawaken Dormant HIV Infection

March 24, 2014 2:34 pm | News | Comments

Scientists report that compounds they hoped would “wake up” dormant reservoirs of HIV inside immune system T cells— a strategy designed to reverse latency and make the cells vulnerable to destruction— have failed to do so in laboratory tests. Read more...


Japan OKs World-First ADPKD Therapy

March 24, 2014 11:03 am | News | Comments

Otsuka Pharmaceutical Co. Ltd. announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Read more...         

New Analyses Show Edoxaban Comparable to Warfarin

March 24, 2014 10:53 am | News | Comments

Daiichi Sankyo Co. Ltd. announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two Phase 3 edoxaban studies. Read more...

Emmaus Sickle Cell Drug Hits Phase 3 Endpoints

March 21, 2014 3:04 pm | News | Comments

Emmaus Life Sciences Inc. announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial. Read more...

Endocyte Drug Slows Lung Cancer Progression

March 21, 2014 2:55 pm | News | Comments

Endocyte Inc. announced results from a Phase 2b trial, which showed that the study met the primary endpoint for the combination of vintafolide and docetaxel in folate receptor-positive recurrent non-small cell lung cancer patients. Read more...  

Substance Makes Glioblastoma Cells Explode

March 21, 2014 2:39 pm | News | Comments

Researchers have discovered that a substance called Vacquinol-1 makes cells from glioblastoma, the most aggressive type of brain tumor, literally explode. When mice were given the substance, tumor growth was reversed and survival was prolonged. Read more...

Investigational Drug Evaluated in Newborns with Rare Disorder

March 21, 2014 2:31 pm | News | Comments

Children with a rare genetic disorder that causes missing and malformed teeth, sparse hair and the inability to perspire are born without a key developmental protein. A clinical trial now underway aims to see if the void can be filled with replacement-protein therapy. Read more...

Novartis Starting New Head-to-Head Psoriasis Trial

March 21, 2014 2:10 pm | News | Comments

Novartis announced that a new Phase 3b head-to-head study of IL-17A inhibitor secukinumab (AIN457) versus Stelara (ustekinumab) in moderate-to-severe plaque psoriasis has started patient enrollment. Read more..           

Oral Chemotherapy Trial Launched in New Zealand

March 21, 2014 11:00 am | News | Comments

Kinex Pharmaceuticals announced that the company has received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand. Read more...        

Janssen Halts Schizophrenia Drug Trial on Positive Efficacy

March 20, 2014 3:10 pm | News | Comments

Janssen Research & Development announced that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of an investigational schizophrenia treatment. Read more...

Hawaii Sues BMS, Sanofi Over Plavix

March 20, 2014 2:43 pm | by Jennifer Sinco Kelleher | News | Comments

Hawaii's attorney general is suing the makers of a widely prescribed blood thinner that he says a significant portion of the state's population has difficulty metabolizing. The suit names Bristol-Myers Squibb and Sanofi-Aventis as defendants. Read more...

Agenus-GSK Lung Cancer Drug Disappoints in Trial

March 20, 2014 2:18 pm | News | Comments

Shares of Agenus tumbled more than 13% Thursday before markets opened and after the biopharmaceutical released more ineffective study results from its collaboration with GlaxoSmithKline. Read more...               

How Personalized Medicine Works: Bananas and Biomarkers

March 20, 2014 11:13 am | Videos | Comments

In today's video, Andrew Wiecek discusses how personalized medicine works by highlighting the importance of biomarkers (and bananas) and showing that they play a key role in identifying genetic variations associated with disease.       

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.